ImetelChat

The silence about the "QT interval" is deafening. As far as I know, there has been no information officially from Geron. This seems to be a study that someone needs but is not part of OS or safety considerations. BP was seeking information, but I don't believe he has found it yet. At the moment, thi...

(From bp)---" Anyway no bad news here and the new hire seems directed toward partnerships". -------------------------------------------------------------- Everything appears to be in place: staff, manufacturing, phase 2's (successfully completed) & phase 3's (pending), ASH2021, possible partners (NV...

(From Biopearl)---"This is new and may as noted by others on this board conceivably prolong the entire study unless the sub study will be of very short duration and designed to answer a specific question (this does appear to be the case) and recruitment goes rapidly." -------------------------------...

(from Biopearl)-----"Hundreds of patients have received Imetelstat at this point and each of them had to have ECGs (and some maybe signal averaged ECGs) looking for arrhythmia issues and QT prolongation which is a marker for trouble. Janssen scientists also looked and did not find if I remember corr...

MD Anderson can use Imetelstat (IMET) for cancer treatments, advance it by research, and endorse IMET internationally. They have found independently that IMET works well on blood cancers, and they are now pursuing other advanced applications, including combinations. MD Anderson, when it comes to can...

From Mayo Clinic to MD Anderson. The early excitement about Imetelstat (IMET) started when Dr. Tefferi at Mayo found that IMET could do more than treat ET, where the term, "Tantamount to a cure" originated. Now new excitement & possibilities are now being defined by MD Anderson, whose primary missio...

My thoughts go to MD Anderson and the previous successes they have had with Imetelstat. I would like to understand what they have done with Imetelstat in the past, and what they plan to do in the future. It seems to me that MD Anderson is the new Mayo Clinic for Imetelstat. They have the experience ...

Great Britain (MHRA) + Japan + MD Anderson successes+ EMA previous positive comments (all material for November 9)

This makes Nov. 9 more intriguing. I am very interested in the MD Anderson connection and their apparently very successful experiences with Imetelstat.

Favorable comments and/or an endorsement from Dr. Swaminathan & MD Anderson would get everyone's attention. November 9th will tell us about their involvement with Imetelstat, and the future potential from their perspective, which would likely include something about IMET 2.0. That is about 2 weeks f...

(John Scarlett's excitement)--- There have been several comments about JS's & Aleksandra Rizo's excitement, with the focus on the November Investor's Conference (date?). From the statement below, it is easy to get upbeat about the near future. "So stay tuned--". *********************************** (...

These comments are very encouraging. I am looking forward to the Nov. Investors' Conference, and then ASH-2021 ***************************************** Question from Justin Walsh -- B. Riley Securities -- Analyst Answer from John Scarlett -- Chairman and Chief Executive Officer of Geron "Yes. I thi...

With competition coming, Geron needs to solidify its blood cancer lead with partners and/or a buyout. Geron needs deep pockets to stay ahead (patents, trials, approvals, IMET 2.0, combinations, etc.). I think they know that.

Geron has concentrated on blood cancers, where they have had considerable successes. There were early attempts with some solid tumors that did not succeed. I believe that was in part due to the delivery system that this article addresses. IMET 2.0 will likely be about delivery systems, as well as al...

This all takes money. The case for partners seem to be to everyone's advantage. Geron remains as an independent company (until there is a buyout) with a rising stock price, the AML combination trials get off of the ground (also ALL), and research gets underway on solid tumor combinations. Geron is a...

EHA 2021 | Imetelstat efficacy is independent of molecular subtypes in R/R LR-MDS Valeria Santini • 18 Jun 2021 EHA 2021 Anemia Myelodysplastic Syndromes Imetelstat IMerge Valeria Santini, MD, University of Florence, Florence, Italy, shares an update on the Phase II/III IMerge study (NCT02598661) of...

There are 6 considerations for blood cancers, especially MF and MDS:

1. OS
2. TI
3. Disease modification
4. Safety
5. Effectiveness
6. Current patient need

Imetelstat does well in all of these categories medically, reinforced by the 2 EHA2021 posters.

Telestat

(IMO) JNJ/Janssen still has an eye on Imetelstat. Dr. Rizo and others that spent time at Janssen are not at Geron by accident. Imetelstat has had many medical successes, with combination potential yet to be explored.

Very interesting -------The wording from the EMA for OD status needs to be compared with the FDA wording. Is it possible that OD status from the EMA, from a practical point of view, implies much more than the FDA wording. Does the EMA OD status imply that the next step or approval will soon follow (...